[OurCrowd] SaNOtize is conducting Phase II clinical trials of a nasal spray based on nitric oxide as a prevention and early treatment against COVID-19. The trials were approved by Health Canada, where the company is based, after independent laboratory tests by the Institute for Antiviral Research at Utah State University confirmed the company’s Nitric Oxide Releasing Solution (NORSTM) inactivated more than 99.9% of SARs-CoV-2, the virus that causes COVID-19, within two minutes.
SaNOtize expects the trials to demonstrate that its formulation safely kills the virus before it can incubate in the nasal passages and spread to the lungs, preventing the onset of COVID-19. The company believes it will also be effective against other viruses, dermal and respiratory diseases and conditions including influenza, H1N1, rhinosinusitis, onychomycosis, athlete’s foot and acne.
Prof. Ferid Murad of Stanford University won the Nobel Prize for discovering the properties of nitric oxide. He now sits on the SaNOtize board of directors.
Read more about SaNOtize in the News section below and watch a video about the clinical trial. |